Gilenia is a brand name medication that contains the active ingredient fingolimod. It belongs to a class of drugs known as sphingosine-1-phosphate receptor modulators. Gilenia is primarily used as an immunomodulatory therapy for the treatment of multiple sclerosis (MS).
The action of Gilenia involves binding to specific receptors on lymphocytes, a type of white blood cell. By doing so, it prevents these cells from reaching certain areas of the body such as the central nervous system, where they normally contribute to the inflammation associated with MS. This mechanism of action helps to reduce the frequency and severity of MS relapses, slows down the progression of physical disability, and delays the accumulation of brain lesions.
Gilenia is administered orally, usually as a once-daily tablet. The dosage is adjusted according to the patient's individual response and tolerability. Prior to starting Gilenia, individuals are typically required to have a complete blood count test, liver function tests, and undergo a thorough ophthalmic examination to assess their eligibility for treatment.
Although Gilenia can be effective in managing MS, it is associated with various potential side effects. Common adverse reactions include headaches, influenza-like symptoms, diarrhea, elevated liver enzymes, and reduction in heart rate, among others. Additionally, Gilenia use has been linked to increased risk of infections, macular edema, and potential effects on cardiac conduction. Therefore, close monitoring and regular check-ups are vital during Gilenia treatment.
It is important to note that this definition is solely focused on the medication Gilenia and not on other contexts where the term "Gilenia" may be used.
